



Final Appraisal Recommendation
Advice No: 1512/1612 – June 2012

Nevirapine (Viramune®)

Limited submission by Boehringer Ingelheim Ltd

Recommendation of AWMSG

Nevirapine (Viramune®) prolonged release tablets are recommended as an option for use within NHS Wales in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus type 1 (HIV-1) infected adults, adolescents, and children three years and above and able to swallow tablets.

Prolonged release tablets are not suitable for the 14-day lead-in phase for patients starting nevirapine. Other nevirapine formulations, such as immediate release tablets or oral suspension should be used.

Most of the experience with Viramune® is in combination with nucleoside reverse transcriptase inhibitors (NRTIs). The choice of a subsequent therapy after Viramune® should be based on clinical experience and resistance testing.

Additional note:

- AWMSG of the opinion that nevirapine (Viramune®) prolonged release tablets may be appropriate for specialist only prescribing within NHS Wales for the indication under consideration.

In reaching this recommendation AWMSG took account of the AWMSG Secretariat Assessment Report (Adults), AWMSG Secretariat Assessment Report (Adolescents and children), the preliminary appraisal recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (Adults), clinical expert opinion (Adolescents and children), lay/patient/carer perspective and discussions at AWMSG.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Marketing authorisation holder on first issue:	Boehringer Ingelheim Ltd
Date of first issue	June 2012
Last reviewed	August 2016



NHS Evidence has accredited the process used by the All Wales Medicines Strategy Group (AWMSG) to produce guidelines. Accreditation is valid for three years from October 2011 and is applicable to guidance produced using the processes described on the AWMSG website. More information on accreditation can be viewed at www.evidence.nhs.uk

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group Final Appraisal Recommendation – 1512/1612:
Nevirapine (Viramune®) June 2012

